By Daniela Schardinger published on Forbes.com After regulatory approval, medtech startups enter a uniquely exposed phase. The product is cleared, years of development are behind them and expectations rise quickly. Boards want validation. Investors want proof of market response. Regulators expect post-market vigilance. Revenue becomes the most visible signal of success. Often, it feels like the only one. This is why many startups move quickly from approval to launch. Not nece

Expert Panel Contribution — Daniela Schardinger Every year, thousands of health tech startups launch with glossy pitches about revolutionsing healthcare. But few stay the course and make the long-term impact that investors and the healthcare system demand. We reached out to Health Tech World and Femtech World members who’ve watched the innovation cycle from every angle with the following question: What’s a hard truth about health innovation that most startups don’t want to

Interview with Daniela Schardinger on Health Tech World : On Innovation, Systems Change and the Real Cost of Progress Q: Your career spans startups, global health initiatives, and emerging tech. What’s the common thread that’s guided your journey? A: Curiosity and a commitment to solving real problems. Whether I’ve been working with a scrappy startup or sitting at a global policy table, the throughline is the same: identifying overlooked needs and finding practical, scalable

Forbes Expert Panel Contribution — Daniela Schardinger. From economic uncertainty to rapid technological change, an unpredictable economic environment is presenting an ongoing challenge for industry leaders. While time-tested strategies still have value, embracing unconventional tactics can not only unlock new opportunities but also take a business to the next level. In a marketplace that rewards adaptability, experimentation and fresh thinking, staying ahead requires more th